CTLA-4

(redirected from Ctla4)
Also found in: Acronyms, Wikipedia.

CTLA-4

References in periodicals archive ?
A linkage analysis of the CTLA4 gene region in Finnish patients with type 1 diabetes.
CTLA4 is expressed on T cells, where it functions as a fundamental negative regulator of T-cell activation.
In addition, we genotyped a series of 40 individuals for both CTLA4 and CYP19A1 polymorphisms by H-ARMS-PCR analysis with different thermal cyclers (iCycler[R] by Bio-Rad, Px2[R] by Hybaid, and PTC-100[R] by MJ Research) and in different laboratories, and we obtained fully concordant results, demonstrating the robustness and reproducibility of this approach.
CTLA4 is a T-cell regulatory protein which is one of the immune system's natural "off switches", which may have potential use in organ transplantation and autoimmune diseases.
We undertook the current study to investigate associations of the CTLA4 (-318, +49 G/A, and CT60) polymorphisms and haplotypes with susceptibility to AIP in Chinese patients as well as their associations with extrapancreatic manifestations.
In addition animals with CT26 colorectal tumours had 27% inhibition of tumour growth when treated with BNC105 as a monotherapy and 14% inhibition in tumour growth when treated with an antibody targeting CTLA4.
OTCQB: TIKRF) today announced that it will proceed with a pre-clinical plan for the generation and verification of new antibodies targeting the modulation of CTLA4 and PD1 cancer checkpoints.
AST-VAC1 may be used to enhance the activity of recently approved or experimental immune checkpoint inhibitors that target the CTLA4, PD1, or other pathways by providing a potent stimulator of tumor-targeting immune responses.
The addition of other key targets including hENT1, TS, CTLA4, TLE3, LAG3 and TP is scheduled in a few weeks.
The expression of immune regulatory targets in the studied population suggests that targeted therapies that inhibit immune checkpoints such as PD-1, PD-L1, CTLA4, B7-H3, and IDO1 may be especially effective in patients with luminal breast cancers, particularly those with ER-positive and HER2-negative disease.
Maxygen used its MolecularBreeding(TM) directed evolution platform to generate a library of novel CTLA4 proteins with significantly higher specific binding to human B7 ligands.